Cato Research is a full-servicecontract research and development organization with international resourcesdedicated to helping pharmaceutical and biotechnology…
From Cato Research Ltd. – 26 Apr 2016 17:17:54 GMT
– View all Sa…
Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…
From Ajinomoto Althea, Inc. – 26 Apr 2016 17:07:48 GMT
– View all San…
Outstanding cancer research company seeks candidate to be responsible for cell culture media preparation, processing and expansion. Will perform cell transfections, clonal selection and analytical characterization, and provide detailed documentation […
Enabling Legendary Discovery: BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providi […
CUPERTINO, Calif., April 26, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public. The gross proceeds to DURECT from this offering are expected to be $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by DURECT. All of the shares in the offering are to be sold by DURECT. The offering is expected to close on or about April 29, 2016, subject to the satisfaction of customary closing conditions. DURECT has granted the underwriters a 30-day option to purchase up to an aggregate of 1,800,000 additional shares.
Stifel acted as sole book-running manager for the offering and Laidlaw & Company (UK) Ltd. acted as co-manager.
Felix Theeuwes, our Chairman and Chief Scientific Officer, and David Hoffmann, one of our directors, have agreed to purchase 360,000 shares of common stock in this offering, at the public offering price, for an aggregate purchase price of $450,000.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and is effective. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov. When available, copies of the final prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About DURECT Corporation
DURECT is a biopharmaceutical company focused on two areas of active drug development: new therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its Epigenomic Regulator Program. Its drug development expertise is being applied primarily to the fields of pain management, CNS disorders, acute organ injury and metabolic diseases such as NAFLD/NASH. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. Late stage development programs of this nature include POSIMIR™ (SABER®-Bupivacaine) and REMOXY® (ORADUR®-oxycodone). DURECT’s Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.
NOTE: POSIMIR®, ORADUR® and SABER® are trademarks of DURECT Corporation. REMOXY, POSIMIR and DUR-928 are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
This press release includes forward-looking statements as defined under federal law. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “may,” “should,” “could,” “will,” “would,” and “will be,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause the Company’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the preliminary prospectus supplement, which has been filed with the SEC, and the risk factors incorporated by reference therein from the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. The Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
SOURCE DURECT Corporation
SOUTH SAN FRANCISCO, Calif., April 26, 2016 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2016 financial results after market close on Tuesday, May 3, 2016. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.
Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 97470871. The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com. The webcast will be archived and available for replay for 30 days after the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.
Contact: Ryan Maynard
Media Contact: Susan C. Rogers, Rivily, Inc.
SOURCE Rigel Pharmaceuticals, Inc.
We are a biotherapeutics company, located in Torrey Pines, looking for a year-round, paid intern to help with our Molecular Biology department. We require a commitment of 15-20 hours/week, mostly in the morning. A majority of the position will involv […
Description Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a
From Celgene Corporation – 26 Apr 2016 04:15:57 GMT
– View all San Die…
Principal Scientist, Protein Homeostasis & Structural Informatics – Celgene Corporation – San Diego, CA
7+ years post-doctoral experience of inter-disciplinary computational and molecular/chemical biology research in university, hospital or biotechnology…
From Celgene Corporation – 26 Apr 2016 04:15:57 GMT
– View all San Diego …
7+ years post-doctoral experience of inter-disciplinary computational and drug discovery research in university, hospital or biotechnology environments….
From Celgene Corporation – 26 Apr 2016 04:15:54 GMT
– View all San Dieg…